OTC Regulatory Pathway Needs NDA Flexibility, Monograph Scope – Sharfstein
This article was originally published in The Tan Sheet
Executive Summary
Former FDA deputy commissioner Joshua Sharfstein, noting public health advocates’ disappointment with results from Sunscreen Innovation Act requirements, proposes an OTC drug review pathway that combines elements of the NDA and monograph systems and would require legislation to create.
You may also be interested in...
Unilever’s Dove Recommits To ‘Real Women’ Against Rising AI Threat
Unilever PLC’s Dove and Baby Dove brands continue tackling prominent social causes with a vow to be responsible about representing women realistically in advertising in the age of AI and a renewed commitment to closing the Black maternal care gap.
L’Oreal Joins J&J And Major Retailers Defending Benzene Class Actions In Federal Courts
Benzoyl peroxide-based acne drug products and their alleged proclivity to become contaminated with carcinogenic benzene are at the center of putative class actions filing against L’Oreal in federal courts around the US.
National Advertising Division Shuts Down Skincarebrandsreviews Website
NourishMax agreed to discontinue “top pick” claims for its Diamond Infused Eye Cream and fold up its website that looked suspiciously to NAD like advertising in the guise of independent, honest reviews.